Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat obstructive sleep apnea (OSA). Its lead solution platform is the Genio system, described as an FDA approved and CE-Mark validated, user-centered, bilateral neurostimulation therapy for moderate to severe OSA, intended as an alternative for people who cannot tolerate, have failed, or refused CPAP therapy. The company is based in Mont-Saint-Guibert, Belgium.

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat obstructive sleep apnea (OSA). Its lead solution platform is the Genio system, described as an FDA approved and CE-Mark validated, user-centered, bilateral neurostimulation therapy for moderate to severe OSA. The company is based in Mont-Saint-Guibert, Belgium.

A medical technology company focused on innovative solutions to treat obstructive sleep apnea, with the Genio system as its lead solution platform.

• Genio system

  A patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA; described as an FDA approved and CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA.

1. 1| Nyxoahnyxoah.com
2. 2About Nyxoah | Nyxoahnyxoah.com
3. 3Nyxoah (Belgium)wikidata.org
4. 4Nyxoah Announces Closing of Nasdaq Initial Public Offering and Underwriters’ Full Exercise of Option to Purchase Additional Sharesfinance.yahoo.com
5. 5Nyxoah Announces Intention to Launch an Initial Public Offering on Euronext Brusselsfinanznachrichten.de
6. 6Nyxoah appoints new CFOfinanznachrichten.de
7. 7Nyxoah launches its Initial Public Offering on Euronext Brusselsfinance.yahoo.com
8. 8Nyxoah raises €25 million in private funding roundfinanznachrichten.de